FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2951491591> ?p ?o ?g. }

• W2951491591 endingPage "776" @default.
• W2951491591 startingPage "775" @default.
• W2951491591 abstract "Background: Since the era of therapy targeted by tyrosine kinase inhibitors (TKIs), the prognosis of acute lymphoblastic leukemia (ALL) in adult Philadelphia chromosome positive (Ph +) has been significantly improved. Aims: We evaluate in this study the outcome of adult Ph + ALL treated with TKI associated with chemotherapy. Methods: Our study is retrospective, including cases of de novo Ph + adult ALL diagnosed in the Hematology Department of Hedi Chaker Hospital of Sfax from January 2009 to March 2018. Cytogenetic analysis and research Bcr-Abl transcript was performed for all patients. They were treated according to the GRAAPH 2005 protocol. TKI, Imatinib, was used at a dose of 600 to 800 mg/day. Bone marrow allograft has been indicated in patients younger than 50 years, in complete remission and with an HLA compliant intra-familial donor. The current study reports the clinical features and treatment outcome of patients with Ph + ALL. Results: There were 13 patients diagnosed with Ph + ALL among 51 with ALL (25%). The median age at diagnosis was 44 years (range 20-54 years) and the sex ratio was 0.62. The presence of t (9.22) was found in 8 cases, for all patients with a conclusive karyotype, 5 of them had additional abnormalities. Twelve had a positive Bcr-Abl transcript. One patient had a positive Bcr-Abl transcript but the cytogenetic study was not concluded. Complete remission (CR) was noted in 92% of cases. Eight patients (age <50 years) were on allograft indications, seven of them had a compatible HLA donor. Of these, five patients had an allograft: four patients are alive in major molecular response after a mean follow-up of 5 years (1-7 years). One patient died in post-transplant by acute GVH. For the 8 patients who did not have an allograft, 4 unfortunately died, the 4 others are alive in major molecular response after a mean follow-up of 4 years (1-7 years). Summary/Conclusion: Before the TKI era, adult Ph + ALL had a poor prognosis with unsatisfactory CR and survivals not exceeding 40%. Allogenic stem cell transplantation remains the only curative option for patients with suitable matched donors. Since the introduction of TKIs in chemotherapy regimens, the prognosis has been much improved, leading to a CR rate exceeding 80% in the literature, and an event-free 5-year survival rate exceeding 70%t, this was also found in our series." @default.
• W2951491591 created "2019-06-27" @default.
• W2951491591 creator A5001702374 @default.
• W2951491591 creator A5002016519 @default.
• W2951491591 creator A5030466929 @default.
• W2951491591 creator A5034139361 @default.
• W2951491591 creator A5034909835 @default.
• W2951491591 creator A5049435131 @default.
• W2951491591 creator A5051956051 @default.
• W2951491591 creator A5057440018 @default.
• W2951491591 creator A5064935215 @default.
• W2951491591 creator A5067377366 @default.
• W2951491591 creator A5083638618 @default.
• W2951491591 creator A5085542719 @default.
• W2951491591 creator A5086627530 @default.
• W2951491591 creator A5087409372 @default.
• W2951491591 date "2019-06-01" @default.
• W2951491591 modified "2023-09-24" @default.
• W2951491591 title "PB1681 OUTCOME OF PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE ALL IN SOUTHERN TUNISIA: ABOUT 13 CASES" @default.
• W2951491591 doi "https://doi.org/10.1097/01.hs9.0000565240.15881.a9" @default.
• W2951491591 hasPublicationYear "2019" @default.
• W2951491591 type Work @default.
• W2951491591 sameAs 2951491591 @default.
• W2951491591 citedByCount "0" @default.
• W2951491591 crossrefType "journal-article" @default.
• W2951491591 hasAuthorship W2951491591A5001702374 @default.
• W2951491591 hasAuthorship W2951491591A5002016519 @default.
• W2951491591 hasAuthorship W2951491591A5030466929 @default.
• W2951491591 hasAuthorship W2951491591A5034139361 @default.
• W2951491591 hasAuthorship W2951491591A5034909835 @default.
• W2951491591 hasAuthorship W2951491591A5049435131 @default.
• W2951491591 hasAuthorship W2951491591A5051956051 @default.
• W2951491591 hasAuthorship W2951491591A5057440018 @default.
• W2951491591 hasAuthorship W2951491591A5064935215 @default.
• W2951491591 hasAuthorship W2951491591A5067377366 @default.
• W2951491591 hasAuthorship W2951491591A5083638618 @default.
• W2951491591 hasAuthorship W2951491591A5085542719 @default.
• W2951491591 hasAuthorship W2951491591A5086627530 @default.
• W2951491591 hasAuthorship W2951491591A5087409372 @default.
• W2951491591 hasBestOaLocation W29514915911 @default.
• W2951491591 hasConcept C104317684 @default.
• W2951491591 hasConcept C126322002 @default.
• W2951491591 hasConcept C138626823 @default.
• W2951491591 hasConcept C141071460 @default.
• W2951491591 hasConcept C167135981 @default.
• W2951491591 hasConcept C187212893 @default.
• W2951491591 hasConcept C194409129 @default.
• W2951491591 hasConcept C2776694085 @default.
• W2951491591 hasConcept C2777583451 @default.
• W2951491591 hasConcept C2778461978 @default.
• W2951491591 hasConcept C2778729363 @default.
• W2951491591 hasConcept C2778904597 @default.
• W2951491591 hasConcept C2909962599 @default.
• W2951491591 hasConcept C3019892230 @default.
• W2951491591 hasConcept C54355233 @default.
• W2951491591 hasConcept C71924100 @default.
• W2951491591 hasConcept C86803240 @default.
• W2951491591 hasConcept C90924648 @default.
• W2951491591 hasConceptScore W2951491591C104317684 @default.
• W2951491591 hasConceptScore W2951491591C126322002 @default.
• W2951491591 hasConceptScore W2951491591C138626823 @default.
• W2951491591 hasConceptScore W2951491591C141071460 @default.
• W2951491591 hasConceptScore W2951491591C167135981 @default.
• W2951491591 hasConceptScore W2951491591C187212893 @default.
• W2951491591 hasConceptScore W2951491591C194409129 @default.
• W2951491591 hasConceptScore W2951491591C2776694085 @default.
• W2951491591 hasConceptScore W2951491591C2777583451 @default.
• W2951491591 hasConceptScore W2951491591C2778461978 @default.
• W2951491591 hasConceptScore W2951491591C2778729363 @default.
• W2951491591 hasConceptScore W2951491591C2778904597 @default.
• W2951491591 hasConceptScore W2951491591C2909962599 @default.
• W2951491591 hasConceptScore W2951491591C3019892230 @default.
• W2951491591 hasConceptScore W2951491591C54355233 @default.
• W2951491591 hasConceptScore W2951491591C71924100 @default.
• W2951491591 hasConceptScore W2951491591C86803240 @default.
• W2951491591 hasConceptScore W2951491591C90924648 @default.
• W2951491591 hasIssue "S1" @default.
• W2951491591 hasLocation W29514915911 @default.
• W2951491591 hasLocation W29514915912 @default.
• W2951491591 hasOpenAccess W2951491591 @default.
• W2951491591 hasPrimaryLocation W29514915911 @default.
• W2951491591 hasRelatedWork W1540387295 @default.
• W2951491591 hasRelatedWork W1963577235 @default.
• W2951491591 hasRelatedWork W1969555336 @default.
• W2951491591 hasRelatedWork W2013094827 @default.
• W2951491591 hasRelatedWork W2053904016 @default.
• W2951491591 hasRelatedWork W2060655150 @default.
• W2951491591 hasRelatedWork W2082176708 @default.
• W2951491591 hasRelatedWork W2087090648 @default.
• W2951491591 hasRelatedWork W2109292561 @default.
• W2951491591 hasRelatedWork W2258013242 @default.
• W2951491591 hasVolume "3" @default.
• W2951491591 isParatext "false" @default.
• W2951491591 isRetracted "false" @default.
• W2951491591 magId "2951491591" @default.
• W2951491591 workType "article" @default.